Business Wire

C3.ai Digital Transformation Institute Announces Call for Proposals for AI to Transform Cybersecurity and Secure Critical Infrastructure

21.12.2021 17:00:00 EET | Business Wire | Press release

Share

The C3.ai Digital Transformation Institute invites scholars, software developers, and researchers to advance the science of digital transformation with artificial intelligence (AI) designed to harden information security (Infosec) and secure critical infrastructure.

“Cybersecurity is an existential issue,” said Thomas M. Siebel, Chairman and CEO of C3 AI, a leading enterprise AI software provider. “We are assembling the best minds on the planet to develop innovative AI to attain a step-function improvement in securing IT, OT, and critical infrastructure systems.”

“Advanced AI and machine learning offer the best opportunity to design robust defensive systems,” said C3.ai DTI Co-Director S. Shankar Sastry of UC Berkeley, whose area of research expertise is cybersecurity. “This call for proposals will help design the defenses necessary to securely shield the digital transformation of our economy.”

“We aim to develop AI techniques to identify and neutralize malware, ransomware, phishing attacks, and prevent the weaponization of innocent insiders,” said C3.ai DTI Co-Director R. Srikant of the University of Illinois at Urbana-Champaign, an expert in AI and networks.

Immediate Call for Proposals: AI to Transform Cybersecurity and Secure Critical Infrastructure.
Topics for research awards may include, but are not limited to, the following:

  1. AI techniques to identify previously unknown malware, ransomware, and zero-day vulnerabilities, enabling isolation and neutralization
  2. AI-enabled network and system crawlers that can continuously search and identify persistent access mechanisms (backdoors), bots, remote access toolkits (RATS), stagers, and Trojans
  3. AI forensics and attribution techniques to identify sources of attacks
  4. AI techniques to automate simulated adversarial attacks to identify system and network vulnerabilities
  5. AI techniques to accurately identify and enable the neutralization of phishing attacks
  6. Change management techniques to prevent the weaponization of innocent insiders
  7. AI techniques to detect the presence of advanced persistent threats and insider threats
  8. AI-enabled network and/or system crawlers that access and continuously evaluate system security levels
  9. AI techniques, perhaps in supervised or unsupervised learning, to provide early detection of system and/or network anomalies that might be indicative of unauthorized access, denial of service, or data exfiltration
  10. Techniques and methods to enable the development of AI algorithms that are resilient to adversarial attacks
  11. AI techniques to identify concentration risk in the software and computer supply chain
  12. Change management to transform organizational behavior to manifest best practices in cyber hygiene
  13. Techniques to respond to attacks at the organizational and societal level

This third call for proposals is open now, with a submission deadline of February 7, 2022. Researchers are invited to learn more about C3.ai DTI and how to submit their proposals for consideration at C3DTI.ai. Award winners will be announced in March 2022, with a start date around June 1, 2022. Award winners may take part in the annual C3.ai DTI Research Symposium, to be held March 22-24, 2022, in Miami, Florida.

Up to USD $10 million in cash awards will be funded from this third call, ranging from USD $100,000 to $1,000,000 each. In addition to cash awards, C3.ai DTI recipients will be provided with significant cloud computing, supercomputing, data access, and AI software resources and technical support provided by Microsoft and C3 AI. This will include unlimited use of the C3 AI® Suite hosted on the Microsoft Azure Cloud, and access to high-performance computing resources at the Lawrence Berkeley National Laboratory and the National Center for Supercomputing Applications (NCSA) at the University of Illinois at Urbana-Champaign. All science developed from C3.ai DTI funded projects accrues to the public domain.

Establishing the New Science of Digital Transformation
C3.ai DTI focuses its research on AI, machine learning, IoT, big data analytics, human factors, organizational behavior, ethics, and public policy. The Institute supports the development of ML algorithms, data security, and cybersecurity techniques. C3.ai DTI research analyzes new business operation models, develops methods of implementing organizational change management and protecting privacy, and amplifies the dialogue around the ethics and public policy of AI.

About C3.ai Digital Transformation Institute
C3.ai Digital Transformation Institute represents an innovative vision to take AI, ML, and big data research in a consortium model to a level that cannot be achieved by any one institution alone. Jointly managed by the University of California, Berkeley and the University of Illinois at Urbana-Champaign, C3.ai DTI attracts the world’s leading scientists to join in a coordinated and innovative effort to advance the digital transformation of business, government, and society, and establish the new science of digital transformation. To support the Institute, C3 AI will provide $57,250,000 in cash contributions over the first five years of operation. C3 AI and Microsoft will contribute an additional $310 million in-kind, including use of the C3 AI Suite and Microsoft Azure computing, storage, and technical resources to support C3.ai DTI research.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

C3.ai DTI Contact:
Kap Stann
Communications Manager, C3.ai DTI @ Berkeley
Tel. +1 510-295-9685
Kstann@berkeley.edu

Press Contact
Lisa Kennedy
(415) 914-8336
pr@c3.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye